But we are still taking part in the downstream financials. And over the course of time in the long-term eventually in a substantial number of programs hopefully that really enable us to diversify that portfolio and the number of programs that we have a stake in. So as our partners and collaborators continue to move on. We’re providing more and more opportunity for investors. So in short, RK really through in vitro functional studies is really one place where we’re finding, we’re landing and getting a particular amount of interest in these programs at that point in time. And if needed, possibly in vivo functional studies, which is originally where we thought we would need to go, but we’re finding that more and more companies are, needing assets earlier now after having been a little bit more stagnant during COVID.
Swayampakula Ramakanth: Okay. So the last question from me. I’m glad to see that you’re going to have an abstract at the AACR next month. What are we going to see there in terms of data? And also more how are you planning to utilize these data for commercializing not only your CRO ability, but also your drug developing capabilities?
Jennifer Bath: Yes, so at AACR, we’ll be presenting that T-cell engager bispecific. That Ilse mentioned during her portion of the sharing today. And I’ll go ahead and let Ilse give you the specifics on what will be presented both in the publication and in the presentation at the conference.
Ilse Roodink: Yes, hello, thank you for the question. This is Ilse. What we are going to present at the AACR is the current status of the program. And that the functionality in vitro showing that our T-cell engager is able to activate T-cells in the presence of the TrkB expressing cells, so kind of proof-of-concept in vitro for this bispecific molecule. Is that answering your question?
Swayampakula Ramakanth: Yes, yes. Now the other portion was how you plan to commercialize it, I guess, Jennifer, may I have a comment on it?
Jennifer Bath: Sure. So that program, which is TATX-200 the bispecific program, is actually really our hottest program right now. So that is the one where we have the most people interested. And right now, the way it’s looking like we will commercialize it is through the process of and this is just likely, can’t say for sure until something find on the dotted line. So a lot of companies are fickle and change their mind here and there. But right now, what it’s looking like is we will extend the material transfer agreement and likely exclusivity for a group to investigate whether or not the in vivo functional activity corresponds with what we’re seeing in vitro. And if so, the resulting license would look very similar to the licenses we’ve been discussing in BioStrand, but would include not only already originally financial incentive to have that exclusivity and the material transfer.
But then after the in vivo work, and upfront payments, you actually take control of the product as an in-license. And then relatively early stage milestones beginning with preclinical and IND-enabling, filing through the traditional milestones in the clinic and commercial royalties. So that’s the current plan with TrkBxCD3 bispecific program.
Swayampakula Ramakanth: Perfect, thank you, thank you, Jennifer, for taking all my questions, I appreciate that.
Jennifer Bath: Of course, thank you.
Operator: Your next question will come from the line of Michael Freeman with Raymond James. Please go ahead.
Michael Freeman: Hello Jennifer, Ilse, Brad. Thanks so much for taking our questions. And congratulations on driving progress in so many different corners of the business this quarter. It’s truly impressive. First question is on the – is on Talem’s agreement with Libera Bio. I wonder if you could provide A bit more color on the deal, how milestones are distributed through that agreement? How many targets are contemplated and anything else you could probably share?
